Is Passage Bio Inc (PASG) overvalued? · $25.2M cap
Passage Bio Inc (PASG) is a biotechnology company listed on US.
This page asks whether Passage Bio Inc (PASG) looks expensive on cached numbers — not a short thesis.
No cached income statement for PASG, so there is no earnings base to call rich or cheap.
PASG currently screens at market cap $25.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PASG 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PASG stock page for the full model, not this heading.
Not investment advice.